Doxycycline

Doxycycline

Generic Name

Doxycycline

Mechanism

  • Bacteriostatic effect achieved by binding reversibly to the 30S ribosomal subunit.
  • Inhibits the attachment of amino‑acyl‑tRNA to the A‑site, blocking peptide chain elongation.
  • Eliminates growth of susceptible Gram‑positive, Gram‑negative, and some atypical bacteria (e.g., *Mycoplasma*, *Chlamydia*, *Rickettsia*, *Borrelia*, *Toxoplasma*, and *Plasmodium falciparum*).

Pharmacokinetics

  • Absorption: Rapid; peak plasma concentration in 1–3 h. Food reduces, but does not eliminate, absorption; most significant inhibition by dairy products and calcium‑fortified juices.
  • Distribution: High tissue penetration; not highly bound to plasma proteins (<30 %). Excellent CNS, ocular, bile, and muscle distribution.
  • Half‑life: 18–22 h (oral), enabling twice‑daily dosing.
  • Metabolism & Excretion: Minimal hepatic metabolism. ~80 % excreted unchanged in feces (bile), ~20 % in urine.
  • Drug Interactions: Chelating agents (antacids, calcium, iron, magnesium, aluminum) delay absorption; fluoroquinolones or sulfonamides may increase risk of photosensitivity.

Indications

  • Bacterial infections:
  • Community‑acquired pneumonia, Lyme disease (early stage), *Legionella* and *Ureaplasma*
  • Skin & soft‑tissue infections, acne vulgaris, rosacea, and post‑traumatic joint infections
  • Oropharyngeal and ear infections (children)
  • Endocarditis prophylaxis (selected cases)
  • Vector‑borne diseases:
  • Malaria prophylaxis and treatment for *P. falciparum,* *P. vivax*
  • Tick‑borne diseases: *Ehrlichia chaffeensis,* *Anaplasma phagocytophilum,* *Borrelia burgdorferi* (early Lyme disease)
  • Other indications:
  • Chlamydial cervicitis/urogenital infections
  • Respiratory tract infections in cystic fibrosis
  • Cystic fibrosis exacerbations, antistaphylococcal coverage
  • Empirical coverage for Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome (study‑based)

Contraindications

  • Contraindicated in patients < 8 years and during pregnancy (risk of teeth discoloration, enamel hypoplasia).
  • Caution in lactation; minimal excretion into breast milk—use only if benefits outweigh risks.
  • 819: Photosensitivity—avoid sun exposure and high‑dose ibuprofen, phenothiazines.
  • Taste disturbances, esophageal ulceration—take with full glass of water, keep upright for at least 30 min.
  • Nephrolithiasis & hepatic impairment: monitor renal and hepatic function; adjust dosing if necessary.
  • Ocular use in children < 5 yrs: risk of vision loss; use only for severe cases with close monitoring.

Dosing

IndicationTypical Dose & ScheduleNotes
Adults (bacterial infection)100 mg orally once or twice dailyInitiate 200 mg BID on day 1 for 1–3 days, then 100 mg BID
Malaria prophylaxis100 mg orally once dailyStart 1–2 weeks before travel, continue 4 weeks post‑arrival
Acne / rosacea20–40 mg orally once dailyLower dose may be effective; mitigate GI upset by splitting dose
Children (7–12 yrs)2.5 mg/kg orally BIDInfections >14 days: 5 mg/kg QD
Intravenous200 mg IV every 12 h (then 100 mg every 12 h)For serious infections; monitor serum levels if renal dysfunction

Oral: take with a full glass of water; avoid dairy or antacids for 2 h pre/post‑dose.
Intramuscular: feasible in acute settings, but subcutaneous tissues can develop local irritation.

Adverse Effects

Common (≥ 10 %)
• GI upset (nausea, vomiting, dyspepsia)
• Oral mucositis, taste changes
• Rash; mild photosensitivity

Serious (≤ 5 %)
• Severe photosensitivity → sunburn or dermatitis
• Exacerbation of *Mycobacterium tuberculosis* infection
• Hepatotoxicity: elevated transaminases, cholestatic jaundice
• Esophageal ulcers, perforation (particularly in the elderly or debilitated)
• Osteo‑, and dentinogenesis suppression in developing teeth

> Tip: Avoid concurrent use of high‑dose ibuprofen and phenothiazine agents to reduce photosensitivity risk.

Monitoring

  • Baseline: CBC, CMP, serum creatinine, liver enzymes.
  • During therapy: liver function tests every 2–4 weeks (± malaria prophylaxis > 6 wk).
  • Renal: adjust dosing if eGFR  6 mos therapy in osteoporosis).
  • Skin: evaluate for photosensitivity reactions; counsel on sunscreen.

Clinical Pearls

  • Food Interaction: Calcium, iron, magnesium, and antacids chelate doxycycline; wait 2 h after dairy or chew‑chews.
  • Split-Dose Strategy: Splitting the daily dose (morning & evening) reduces GI upset and improves adherence.
  • Drug‑Drug Synergy: Combining doxycycline with a macrolide can enhance coverage against atypical pathogens while minimizing macrolide‑induced QT prolongation.
  • Optical Penetration: Doxycycline’s excellent ocular uptake is why it’s the drug of choice for prophylaxis of ocular Lyme disease and for treating chronic inflammatory ocular conditions (e.g., uveitis).
  • IV vs Oral: IV doxycycline 200 mg every 12 h is used for severe infections; conversion to oral 100 mg BID can be initiated early if clinical response is observed.
  • Resistance Considerations: Use only when susceptible; avoid in *Streptococcus pyogenes* infections with potential for resistance.
  • Rapid Decay In Pregnancy: Doxycycline’s capability to cross the placenta makes it contraindicated; alternative agents (azithromycin, clindamycin) should be preferred.

--
Key Takeaway: Doxycycline’s broad spectrum, excellent tissue penetration, and convenient twice‑daily oral dosing make it a versatile agent—yet its narrow safety profile regarding teeth development and photosensitivity requires diligent patient education and monitoring.

Medical & AI Content Disclaimers
Medical Disclaimer: Medical definitions are provided for educational purposes and should not replace professional medical advice, diagnosis, or treatment.

AI Content Disclaimer: Some definitions may be AI-generated and may contain inaccuracies. Always verify with authoritative medical references.

Scroll to Top